COVID-19: Page 4
-
Chip Somodevilla/Getty via Getty Images
Core diagnostic growth offsets falling COVID-19 sales at Hologic, Thermo Fisher, Qiagen
Rising demand for core diagnostics offset better-than-feared declines in COVID-19 test sales, shedding light on the companies’ post-pandemic futures.
By Nick Paul Taylor • July 29, 2022 -
Courtesy of Labcorp
Labcorp lowers forecast after Q2 slowdown, will spin off drug development unit
A drop in COVID-19 testing contributed to the company’s second quarter decline, while its base business grew by 1.2% compared to last year.
By Ricky Zipp • July 28, 2022 -
Permission granted by Mayo Clinic
Q&AFriday Q&A: Matthew Binnicker, Mayo Clinic's director of clinical virology, talks COVID-19, monkeypox testing
With cases of both viruses rising across the U.S., clinical laboratories are bringing in staff to ramp up monkeypox testing, even as demand falls for clinical diagnostics of COVID-19.
By Elise Reuter • July 22, 2022 -
Courtesy of Quest Diagnostics
Quest Diagnostics raises 2022 revenue forecast amid continued demand for COVID testing
The company boosted its outlook for the diagnostics unit even as the division posted a 31% decline in revenue in the second quarter.
By Ricky Zipp • July 21, 2022 -
Sarah Silbiger via Getty Images
Defibrillators, chest drains added to FDA's list of device shortages
The defibrillator supply disruption reflects both increased demand and problems sourcing a component, part or accessory.
By Nick Paul Taylor • July 20, 2022 -
400tmax via Getty Images
Diagnostic sector faces a 'challenging set-up' amid economic slowdown: analysts
Goldman Sachs warned there will be “limited visibility over the course of the year,” adding that companies may need to focus more on demonstrating their paths to profitability.
By Nick Paul Taylor • July 19, 2022 -
Permission granted by Columbia University
Q&AFriday Q&A: Ian Lipkin, Columbia epidemiologist, talks COVID-19 testing as U.S. sees another wave
Lipkin explained why he’s not a fan of antigen tests, and stressed the need to keep PCR testing a core part of the pandemic response.
By Elise Reuter • July 15, 2022 -
Mario Tama/Getty via Getty Images
Abbott, Intuitive, J&J to kick off quarterly earnings season next week as recession threat looms
Earnings results are poised to set expectations for the impact of a potential slowdown and shed light on trends with implications for companies including Boston Scientific, Medtronic and Stryker.
By Nick Paul Taylor • July 15, 2022 -
Spencer Platt via Getty Images
Deep DiveWith COVID testing on the wane, small diagnostics companies shift focus
Startups that grew quickly from large contracts are looking nervously to a new future, as demand plummets for mass testing and shifts to homes.
By Elise Reuter • July 13, 2022 -
Carl Court via Getty Images
Hologic, Thermo Fisher roll out respiratory panels for Europe ahead of cold and flu season
Australia’s experience suggests Europe and other parts of the northern hemisphere may face high levels of respiratory disease this winter.
By Nick Paul Taylor • July 12, 2022 -
Phil Walter via Getty Images
SD Biosensor agrees to buy Meridian Bioscience for $1.53B in bid to enter U.S. IVD market
The Cincinnati-based diagnostics company says being acquired will help it enter new markets as part of SD Biosensor, as the COVID-detection business wanes.
By Elise Reuter • July 7, 2022 -
(Photo by Dan Kitwood/Getty Images) via Getty Images
'Little sign' that digital tools are being deployed effectively in fight against COVID outbreak, study finds
To help reduce the spread of the next pandemic, there is “a substantial practical advantage” to integrating the features of multiple smartphone apps, a Scripps Research Translational Institute team found.
By Nick Paul Taylor • July 6, 2022 -
Sarah Silbiger via Getty Images
American Contract Systems' COVID-19 test recall gets Class I label from FDA
Off-site assembly by workers who may not have been properly trained prompted the company to recall COVID-19 tests amid concerns they may yield false results.
By Nick Paul Taylor • Updated July 6, 2022 -
Cameron Spencer via Getty Images
COVID-19 antigen test sensitivity could be as low as 60% with omicron: FDA
The tests have taken a “really big hit in sensitivity” with the omicron variant, raising doubts about the ability of a single test to provide a definitive diagnosis, according to the agency.
By Elise Reuter • July 5, 2022 -
Courtesy of Cue Health Press Kit
Cue Health cuts 170 jobs amid 'economic challenges,' decline in COVID-19 testing
With a contract to test the National Basketball Association, IPO funding and a $481 million government contract, Cue Health grew its headcount more than 10-fold in the pandemic.
By Nick Paul Taylor • June 28, 2022 -
Megan Quinn/MedTech Dive
Deep DiveAs cross-state telemedicine waivers expire, virtual care advocates focus on long-term policy changes
There’s a complication: No one solution to the U.S.’ patchy physician licensing infrastructure has universal buy-in.
By Rebecca Pifer • June 22, 2022 -
Permission granted by La Forma
How a sports apparel company helped one Virginia health system pivot to reusable gowns
Personal protective equipment shortages forced Inova to find new ways to protect workers.
By Samantha Liss • June 21, 2022 -
Spencer Platt via Getty Images
Medical device companies to curb spending as recession threat clouds longer-term outlook: analysts
The supply chain and inflation issues that have affected medical device companies in the first half of 2022 likely will persist through the rest of the year, according to RBC Capital Markets.
By Nick Paul Taylor • June 13, 2022 -
Asia-Pacific Images Studio via Getty Images
GE Healthcare says contrast media production back to full capacity
The shortage of the injectable used for medical imaging started in April, when the company’s plant in Shanghai shut down due to rising COVID-19 cases.
By Nick Paul Taylor • Updated June 17, 2022 -
Justin Sullivan via Getty Images
LabCorp becomes first company to get EUA for direct-to-consumer test for flu, RSV, COVID-19
The kit allows individuals to self-collect nasal swab samples at home to send to LabCorp, which will test for the presence of influenza A and B, respiratory syncytial virus and SARS-CoV-2.
By Nick Paul Taylor • May 18, 2022 -
Courtesy of Dexcom, Nick Jonas Super Bowl kit
Dexcom, Insulet, Tandem start 2022 with revenue growth after weathering omicron surge
All three diabetes technology companies reported that omicron pressured business in January before easing as the quarter progressed.
By Ricky Zipp • May 13, 2022 -
"Government Accountability Office Building" by kafka4prez is licensed under CC BY-SA 2.0
FDA needs testing enforcement discretion policy to improve crisis response, GAO finds
The U.S. Government Accountability Office has recommended that the FDA develop a policy about when to start and stop enforcement discretion for unauthorized tests to avoid some of the problems it faced during the pandemic.
By Nick Paul Taylor • May 13, 2022 -
Drew Angerer via Getty Images
Rising Google searches for procedures suggest recovering demand at medtechs: analysts
Google searches for nonemergent procedures are above pre-pandemic levels, providing another data point to indicate that demand is recovering, according to a Needham report.
By Nick Paul Taylor • May 11, 2022 -
400tmax via Getty Images
Earnings week 3: Procedure rebounds, stock price declines, iRhythm's comeback
AtriCure and Axonics reported procedure volume rebounds and both firms increased their 2022 forecasts. Still, the share prices of the companies dropped late last week.
By Ricky Zipp • May 9, 2022 -
Sarah Silbiger via Getty Images
FDA reveals another Class I COVID-19 test recall as SML pulls 209,000 kits from the market
The SML notice comes one week after the FDA shared details of a recall of 311,100 Celltrion tests that may have been sent to unauthorized users that lack CLIA certification.
By Nick Paul Taylor • May 5, 2022
Previous
